European Union - English - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - west nile recombinant canarypox virus (vcp2017 virus) - immunologicals for equidae, horse, immunologicals - horses - active immunisation of horses from five months of age against west nile disease by reducing the number of viraemic horses. if clinical signs are present, their duration and severity are reduced.

European Union - English - EMA (European Medicines Agency)

zoetis belgium sa - inactivated west nile virus, strain vm-2 - immunologicals for equidae - horses - for the active immunisation of horses of six months of age or older against west-nile-virus disease by reducing the number of viraemic horses.

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

zoetis australia pty ltd - west nile virus (inactivated) (strain vm-2) - unknown - west nile virus (inactivated) (strain vm-2) vaccine-viral active 0.0 - active constituent

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

zoetis australia pty ltd - west nile virus (inactivated) (strain vm-2) - parenteral liquid/solution/suspension - west nile virus (inactivated) (strain vm-2) vaccine-viral active 0.0 u - immunotherapy

European Union - English - EMA (European Medicines Agency)

intervet international bv - inactivated chimaeric flavivirus strain yf-wn - immunologicals - horses - active immunisation of horses against west nile virus (wnv) to reduce clinical signs of disease and lesions in the brain and to reduce viraemia. onset of immunity: 2 weeks after primary vaccination course of two injections. duration of immunity: 12 months.,

United Kingdom - English - VMD (Veterinary Medicines Directorate)

boehringer ingelheim vetmedica gmbh - west nile virus - suspension for injection - vector vaccine - horses

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

zoetis australia pty ltd - equine rotavirus (inactivated); apramycin; amphotericin b; neomycin; thiomersal - misc. vaccines or anti sera - equine rotavirus (inactivated) biological active 1.0 rp; apramycin antibiotic other 0.0 p; amphotericin b antibiotic other 0.0 p; neomycin antibiotic other 0.0 p; thiomersal mercury other 0.1 % - immunotherapy - horse pregnant - rotavirus enteritis | vaccine | equine rotavirus

United States - English - NLM (National Library of Medicine)

teva women's health, inc. - human adenovirus e serotype 4 strain cl-68578 (unii: fkd3duk39i) (human adenovirus e serotype 4 strain cl-68578 - unii:fkd3duk39i) - human adenovirus e serotype 4 strain cl-68578 32000 [tcid_50] - adenovirus type 4 and type 7 vaccine, live, oral is a vaccine indicated for active immunization for the prevention of febrile acute respiratory disease caused by adenovirus type 4 and type 7. adenovirus type 4 and type 7 vaccine, live, oral is approved for use in military populations 17 through 50 years of age. adenovirus type 4 and type 7 vaccine, live, oral should not be administered to pregnant females [see pregnancy (8.1)] . it is not known whether adenovirus type 4 and type 7 vaccine, live, oral can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. naturally occurring infection with adenoviruses has been associated with fetal harm. pregnancy should be avoided for 6 weeks following receipt of vaccine. severe allergic reaction (e.g., anaphylaxis) to any component of adenovirus type 4 and type 7 vaccine, live, oral is a contraindication [see description (11)]. adenovirus type 4 and type 7 vaccine, live, oral should not be administered to individuals incapable of swa

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

zoetis australia pty ltd - bovine herpesvirus 1 - misc. aural, ophthalmic, oro/naso pharyngeal - bovine herpesvirus 1 vaccine-viral active 0.0 p - immunotherapy - cattle - feedlot | beef | bovine | dairy cow - bovine herpesvirus | vaccine | equine rotavirus

Israel - English - Ministry of Health

merck sharp & dohme (israel - 1996) company ltd, israel - rotavirus g1 reassortant; rotavirus g2 reassortant; rotavirus g3 reassortant; rotavirus g4 reassortant; rotavirus p1a[8] reassortant - oral solution - rotavirus p1a[8] reassortant 2.3 x10 ^6 iu/dose; rotavirus g2 reassortant 2.8 x10 ^6 iu/dose; rotavirus g4 reassortant 2.0 x10^ 6 iu/dose; rotavirus g3 reassortant 2.2 x10 ^6 iu/dose; rotavirus g1 reassortant 2.2 x10 ^6 iu/dose - rota virus diarrhea vaccines - rotateq is indicated for the prevention of rotavirus gastroenteritis in infants and children caused by types g1, g2, g3, g4, and g9 when administered as a 3-dose series to infants between the ages of 6 to 32 weeks. the first dose of rotateq should be administered between 6 and 12 weeks of age